Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · Real-Time Price · USD
34.62
+1.37 (4.12%)
May 20, 2026, 4:00 PM EDT - Market closed
Vera Therapeutics Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Vera Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $78.29. The average 1-year stock price forecast is 126.14% higher than the current stock price, while the lowest is $35 (+1.10%) and the highest is $110 (+217.74%).
Price Target: $78.29 (+126.14%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Vera Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 5 | 5 | 4 |
| Hold | 2 | 2 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 10 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $95 → $91 | Buy | Maintains | $95 → $91 | +162.85% | May 15, 2026 |
| Wolfe Research | Wolfe Research | Hold → Buy Upgrades $88 | Hold → Buy | Upgrades | $88 | +154.19% | Mar 11, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $90 → $110 | Strong Buy | Maintains | $90 → $110 | +217.74% | Mar 2, 2026 |
| B of A Securities | B of A Securities | Strong Buy Maintains $48 → $66 | Strong Buy | Maintains | $48 → $66 | +90.64% | Dec 19, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $55 → $95 | Strong Buy | Maintains | $55 → $95 | +174.41% | Dec 19, 2025 |
Financial Forecast
Revenue This Year
47.13M
Revenue Next Year
269.81M
from 47.13M
Increased by 472.48%
EPS This Year
-5.36
from -4.66
EPS Next Year
-3.28
from -5.36
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 128.8M | 534.8M | ||||||
| Avg | 47.1M | 269.8M | ||||||
| Low | 10.0M | 127.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 1,034.6% | ||||||
| Avg | - | 472.5% | ||||||
| Low | - | 170.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -3.97 | -1.14 | ||||||
| Avg | -5.36 | -3.28 | ||||||
| Low | -6.59 | -4.54 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.